ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Low-Frequency Electroacupuncture versus Sham Electroacupuncture for Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07551726 (Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication, with over 50% of diabetic patients affected. Current pharmacologic therapies are limited by adverse effects, highlighting the need for safer alternatives. Preliminary evidence suggests that low-frequency (2 Hz) electroacupuncture (EA) may be beneficial, but high-quality clinical trials investigating its mechanisms are lacking. Methods and Analysis: This prospective, randomized, sham-controlled trial will enroll 92 patients with DPN, who will be randomly allocated in a 1:1 ratio to receive 6 weeks of treatment with either active 2 Hz EA or sham EA. The primary outcomes are overall response rate and lower-limb nerve conduction velocity (NCV). Secondary outcomes include pain intensity assessed using the Visual Analog Scale (VAS), quality of life scores, and serum biomarkers measured by enzyme-linked immunosorbent assay (ELISA), namely nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). All statistical analyses will be conducted according to the intention-to-treat (ITT) principle. Conclusion: This study is expected to provide clinical and mechanistic evidence for the potential role of standardized low-frequency EA as a non-pharmacological treatment option for DPN. Trial Registration: ClinicalTrials.gov Identifier: NCT07551726.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.